Register Login

DiaMedica Therapeutics Inc (DMAC)

(90% Positive) DIAMEDICA THERAPEUTICS INC. (DMAC) Announces Enrollment Update for Preparations Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Dec. 18, 2025, 1:46 p.m.

    📋 DIAMEDICA THERAPEUTICS INC. (DMAC) - Clinical Trial Update

    Filing Date: 2025-12-18

    Accepted: 2025-12-18 08:45:08

    Event Type: Clinical Trial Update

    Event Details:

    DiaMedica Therapeutics Inc (DMAC) Announces Clinical Trial Update DiaMedica Therapeutics Inc (DMAC) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Preparations, request
    • Diseases/Conditions: one additional non-clinical, preeclampsia (PE)
    • Clinical Stage: Phase 2
    • Collaboration: IND
    • Updated Timeline: December 18, 2025

    🔬 Clinical Development Pipeline (DIAMEDICA THERAPEUTICS INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo for DM199 Solution for Injection OTHER Phase PHASE2 Acute Stroke ClinicalTrials.gov
    Recombinant human tissue kallikrein DRUG Phase PHASE2 Acute Stroke ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: DiaMedica Therapeutics Inc
    • CIK: 0001401040
    • Ticker Symbol: DMAC
    • Period End Date: 2025-12-18
    • Document Type: 8-K

Search

News categories